# Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

> **NCT07388563** · PHASE1 · SUSPENDED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (estimated)

## Conditions studied

- Lymphoma, T Cell, Peripheral
- T-cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
- Adult T-cell Leukemia/Lymphoma

## Interventions

- **DRUG:** azacitidine
- **DRUG:** abatacept

## Key facts

- **NCT ID:** NCT07388563
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-03-26
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** New recruitment on hold for a protocol design amendment/modification.
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07388563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07388563, "Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT07388563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*